Evaluation of aflibercept in the treatment of metastatic colorectal cancer

Bibliography

• Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumor vasculature:insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
   PubMed Web of Science ®Google Scholar
• Ferrara N, Alitalo K. Clinical implications of angiogénesis growth factors and their inhibitors. Nat Med 1999;5:1359-64
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF targeted therapy: mechanism of anti-tumour therapy. Nat Rev Cancer 2008;8:579-91
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenensis in life, disease and medicine. Nature 2005;438:932-6
   PubMed Web of Science ®Google Scholar
• Rosen LS. Clinical experience with angiogénesis signaling inhibitors: focus on vascular endotelial growth factor (VEGF) blockers. Cancer Contr 2002;9(Suppl 2):36-44
   PubMedGoogle Scholar
• Ferrara N. Vascular endotherlial growth factor as target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale N, et al. Vascular-specific growth factors and blood vessels formation. Nature 2000;407:242-8
   PubMed Web of Science ®Google Scholar
• Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18
   PubMed Web of Science ®Google Scholar
• Ficher C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PIGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endotelial growth factor: basic science and clinical progress. Endocr Rev 2000;25:581-611
   Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Fukumura D, Rakesh J, Kaid T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25
   PubMed Web of Science ®Google Scholar
• Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:853-63
   Google Scholar
• Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144-6
   PubMed Web of Science ®Google Scholar
• Kim K, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res 1999;59:5209-18
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89
   PubMed Web of Science ®Google Scholar
• Gerber H, Kowalski J, Sherman D, et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-8
   PubMed Web of Science ®Google Scholar
• Holash J, Daveis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007;25:4779-86
   PubMed Web of Science ®Google Scholar
• Scharovsky O, Mainetti E, Rozados V, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogénesis: implications for cellular surrogate marker analysis og antiangiogenesis. Cancer Cell 2005;7:101-11
   PubMed Web of Science ®Google Scholar
• Willett C, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific sntibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7
   PubMed Web of Science ®Google Scholar
• Kuo C, Farnebo F, Yu E, et al. Comparative evaluation of the antitumor activity of anti-angiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98:4605-10
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre P, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8
   PubMed Web of Science ®Google Scholar
• Huang J, Frischer J, Serur A, et al. Regression of established tumours and metastasis by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-90
   PubMed Web of Science ®Google Scholar
• Kim E, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model neuroblastoma. Proc Natl Acad Sci USA 2002;99:11399-404
   PubMed Web of Science ®Google Scholar
• Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascitis, prolonging survival in ovarian cancer model. Cancer Res 2005;11(19):6966-71
   Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Cardi C, et al. VEGF Trap in combination with radiotherapyimproves control in U87 Glioblastoma. Int J Radiat Oncol Biol Phys 2007;67(5):1526-37
   PubMed Web of Science ®Google Scholar
• Dupont S, Joseph ML, Rothenberg et al. Safety and pharmacokynetics of intravenous VEGFR trap in a phase I clinical trial of patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2005;24
   Google Scholar
• Lockart A, Rothenberg M, Dupont J, et al. Phase I study of intravenous vascular endotelial growth factor trap, aflibercept, in patients with advanced solid tumours. J Clin Oncol 2010;28:207-14
   PubMed Web of Science ®Google Scholar
• Tew WP, Gordon M, Murren J, et al. Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumours. Clin Cancer Res 2010;16:358-66
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Khayat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solit tumours. Eur J Cancer 2013;49(1):17-24
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures 2012. American Cancer Society, Atlanta; 2012. Available from: http://www.cancer.org/Research/CancerFacts figures/index
   Google Scholar
• Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 2011;7:25S-30S
   PubMedGoogle Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
   PubMed Web of Science ®Google Scholar
• Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 2000;343:905-14
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
   PubMed Web of Science ®Google Scholar
• Douillard I, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME Study. J Clin Oncol 2010;28:4697
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previoulsy treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Raymond D, Lakomy R, et al. Aflibercept/FOLFIRI vs placebo/FOLFIRI in metastatic colorectal cancer: post-hoc analysis of survival by prior bevacizumab use subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjuvant oxaliplatin-based therapy [Abstract 2260]. Presented at: European Cancer Congress 2013; 27 September – 1 October 2013; Amsterdam, The Netherlands
   Google Scholar